查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1856765

人工智慧在癌症诊断市场的应用、组件、最终用户、癌症类型和技术—全球预测，2025-2032年

AI in Cancer Diagnostics Market by Application, Component, End User, Cancer Type, Technology - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，癌症诊断领域的人工智慧市场规模将达到 13.2709 亿美元，复合年增长率为 22.23%。

关键市场统计数据
基准年 2024 2.6628亿美元
预计年份：2025年 3.2678亿美元
预测年份 2032 1,327,090,000 美元
复合年增长率 (%) 22.23%

人工智慧在癌症诊断领域的快速应用正在重塑临床医生检测、表征和管理肿瘤疾病的方式。演算法解读、增强影像和分子分析技术的进步，使得恶性肿瘤的识别更加早期和准确，同时也重新定义了病理学和放射学实验室的工作流程。随着这些技术变革的推进，相关人员对可重复性、可解释性和合规性的期望也日益提高，临床团队正在寻求能够在不干扰既定诊疗路径的前提下提高诊断信心的工具。

技术开发人员、诊断实验室、学术中心和商业伙伴之间的新型合作正在加速从试验研究到常规临床应用的过渡。同时，数据基础设施和互通性标准的改进正在促进多模态分析，将影像、基因组和临床数据结合，从而建立全面的患者檔案。因此，医疗机构不仅评估人工智慧工具的诊断性能，还评估其操作适用性、整合负担以及在提高患者诊疗效率和改善治疗效果方面能否带来切实的改善。

从概念验证到规模化应用需要权衡临床价值、技术成熟度和报销途径，做出细緻入微的决策。因此，医疗保健和诊断领域的相关人员正在优先考虑严格的检验策略、跨学科管治和相关人员教育，以确保人工智慧解决方案能够以符合伦理、公平和永续的方式融入癌症诊疗流程。

融合技术、不断演进的工作流程以及日益成熟的监管和支付环境如何加速癌症诊断系统的转变

癌症诊断领域正经历着一场变革性的转变，这主要得益于运算能力、数据可用性和演算法复杂性的融合。深度学习模型在放射学和病理学的模式识别方面取得了前所未有的成就，而自然语言处理则简化了从非结构化记录中提取临床相关资讯的过程。同时，基因组分析技术正变得越来越普及，并与分析平台无缝集成，从而能够提供个人化的诊断和治疗方案。

这些技术进步正在重新定义专科医生的角色和工作流程。放射科医师和病理学家日益成为混合诊断流程的协调者，其中自动化预筛检和分诊与专家对复杂或疑难病例的审查相辅相成。同时，医疗系统正积极采用云端优先策略，以实现可扩展的部署，但同时也对资料主权和延迟问题较为担忧的本地部署方案保持警惕。因此，技术采纳呈现出分层式的趋势：试验计画随着相关人员建立经验框架和管治而逐步发展为更广泛的组织部署。

重要的是，不仅存在技术变革，还存在经济和监管变革。随着证据的积累，支付方和政策制定者正在修订应用标准，监管路径也在不断改进，以适应演算法更新和持续学习系统。这些动态正在加速从孤立的点解决方案转向以临床影响、互通性和长期永续性为优先的整合诊断生态系统的转变。

评估2025年美国关税调整如何改变了癌症诊断供应链、筹资策略和投资重点。

美国关税于2025年生效，其累积影响为整个癌症诊断生态系统的采购、供应链规划和资本设备采购带来了新的动态。来自受影响国家和地区的设备和硬体组件的到岸成本有所调整，迫使供应商和医疗系统重新评估供应商合约、库存策略和维护协议。这些成本压力导致供应链多元化，更加重视本地製造伙伴关係，并在评估诊断平台时重新审视整体拥有成本。

硬体采购成本的上涨也间接影响了软体和云端基础服务，因为这改变了IT现代化计划的预算优先事项并调整了投资时间表。为此，一些公司加快了采用云端原生分析和软体授权模式的步伐，将资本支出与营运能力脱钩。另一些公司则优先考虑模组化和可互通的软体架构，以在多供应商环境中保持灵活性，并降低供应商锁定风险——贸易政策的变化加剧了这种风险。

从策略角度来看，相关人员透过签订更长期的服务合约、寻求包含维护和培训的配套服务，以及探索与技术供应商合作开发以实现生产和支援的本地化等方式进行了调整。因此，对韧性、冗余和供应链透明度的日益重视正在影响製造商、经销商和医疗保健提供者之间的采购决策和伙伴关係策略。

详细的細項分析揭示了人工智慧诊断应用、组件、最终用户、癌症类型和技术方面的差异将如何影响其普及和产品设计。

细分洞察揭示了不同应用领域、组件、最终用户、癌症类型和实行技术之间的差异化价值驱动因素。 CT、MRI、PET 和超音波影像工作流程正透过自动化病灶检测、量化和纵向比较工具得到增强，从而支援早期检测和标准化报告。涵盖 DNA 定序、表观遗传分析和 RNA 定序的基因组分析正日益与支持分子分型和标靶治疗选择的分析平台整合。

在组件层面，影像系统和设备的硬体投资辅以服务模式，包括託管服务和专业服务，以支援实施和持续最佳化。软体选择仍然至关重要，基于云端基础的部署提供可扩展性和集中式模型管理，而本地部署解决方案对优先考虑资料驻留和监管控制的机构仍然具有吸引力。诊断实验室关注的是通量和检测验证，医院和诊所关注的是照护现场整合和工作流程效率，製药公司关注的是用于临床试验的生物标记表征，而研究机构关注的是实验灵活性和数据验证。

产品类型特异性考量会影响产品设计与应用。例如，乳癌、大肠癌、肺癌和摄护腺癌等不同类型的癌症在影像学、分子生物学和工作流程方面各有不同的需求，这些需求会影响演算法训练、检验队列和临床终点的设定。此外，深度学习、机器学习和自然语言处理这三项技术的细分凸显了它们各自的互补优势。深度学习擅长以影像为基础的解读，经典机器学习支援结构化资料预测和风险分层，而自然语言处理则能从临床叙述和病理报告中提取洞见。这种细緻入微的观点强调了开发可互通解决方案的必要性，这些解决方案能够根据临床环境进行定制，并利用可靠且具代表性的数据集检验。

美洲、欧洲、中东和非洲以及亚太地区的监管差异、基础设施能力和临床实践模式将如何推动人工智慧诊断应用策略的差异化？

美洲、中东和非洲以及亚太地区的区域动态持续影响战略重点、监管方式和应用模式。在美洲，临床应用通常由能够支持真实世界检验研究的综合医疗系统和大型学术中心所推动。这种环境促进了临床领导者和技术供应商之间的密切合作，从而将试点倡议转化为企业级部署。该地区的采购决策着重于与现有电子健康记录的互通性、业务投资效益以及提高吞吐量和诊断准确性。

在中东和非洲地区，不同的监管法规和报销途径会影响实施策略。该地区的医疗机构通常优先考虑资料管治、隐私合规和跨境互通性，而报销框架在不同司法管辖区之间可能存在显着差异。因此，供应商通常会采取针对特定区域的检验策略，并与当地临床网路建立合作关係，以证明其临床效用并促进监管申报。

亚太地区情况各异，部分市场正经历快速的数位化，而其他市场则面临基础设施瓶颈。某些国家临床应用广泛，使得人工智慧在放射学和病理学领域提升效率、缓解劳动力短缺方面具有显着优势。同时，区域製造业和云端基础设施的投资也促使人们倾向于选择在地化解决方案。总体而言，区域差异凸显了灵活部署模式、兼顾文化差异的临床医生参与以及适应性监管策略对于支持永续应用的重要性。

对供应商策略和协作生态系统的分析表明，现有企业、纯粹的人工智慧开发人员和云端平台正在加速临床整合和商业化进程。

主要企业的动态反映了一个生态系统，在这个生态系统中，传统医疗设备和诊断设备製造商、纯粹的人工智慧供应商、云端服务提供者以及学术衍生公司各自在产品创新和商业化过程中扮演着不同的角色。现有设备製造商利用其临床关係和销售网络，将人工智慧功能整合到其成像和检测平台中；而纯粹的软体公司则专注于快速迭代、演算法优化以及跨异质IT环境的互通性。云端服务供应商和平台公司则支援可扩展的模型部署和联邦学习方法，这些方法在保护资料隐私的同时，也能提高模型的泛化能力。

随着企业将领域专长与演算法技术结合，以加速临床检验和市场准入，策略伙伴关係和共同开发契约日益普遍。併购仍是技术整合的重要途径，尤其是在大型企业整合专业人工智慧能力或拓展分子诊断领域时。此外，支持演算法训练和验证的学术合作也持续进行，为企业提供精选资料集和临床专业知识，从而增强证据包的效力。

相关人员在选择供应商时需要考虑的因素包括临床检验的深度、监管记录、整合支援以及对模型维护和更新的长期承诺。能够展现透明的绩效指标、在不同人群中进行的可靠验证以及清晰的上市后监测路径的公司，更有可能赢得研究中心的信任并实现长期应用。

经营团队需制定切实可行的策略重点，以检验、整合和商业化人工智慧诊断技术，同时确保营运管治和符合伦理规范的治理。

产业领导者应加快对严格的临床检验、管治框架和互通架构的投资，以确保人工智慧工具从试点阶段过渡到值得信赖的临床应用。优先进行前瞻性临床试验、多中心检验和透明的性能报告有助于赢得临床医生的信任和支付方的认可。同时，领导者应建立跨职能的管治委员会，成员包括临床医生、资料科学家、伦理学家和IT专业人员，以管理模型生命週期、版本控制和偏差消除工作。

营运准备同样重要。各机构应投资于可扩展的数据管道、标准化的标註方法以及整合层，以便将人工智慧输出有效地融入临床医生的工作流程。重视模组化软体设计并遵守互通性标准，可以减少整合摩擦，并在多供应商环境中保持灵活性。从商业性角度来看，应考虑采用灵活的采购和定价模式，将供应商奖励与临床结果挂钩，例如基于价值的基本契约和绩效挂钩合约。

最后，要建立伙伴关係，以实现在地化的实施和支援。与区域临床网路、学术中心和生产合作伙伴合作，可以加速技术推广应用，同时解决供应链韧性和监管合规问题。透过将可靠的证据产生与切实可行的营运计划和协作式商业化策略相结合，领导者可以将人工智慧驱动的诊断进步转化为患者照护方面可衡量的改进。

一个稳健的混合方法研究框架，结合多次临床医生访谈、文献综述和同行检验，以确保研究结果具有可操作性和可复製性。

本分析的调查方法结合了多学科证据综合、相关人员咨询和迭代检验，以确保研究结果反映真实世界的情况和新兴趋势。主要资料来源包括对放射科、病理科和分子诊断科的临床医生进行结构化访谈，并辅以与技术负责人、采购负责人和监管专家的咨询。这些工作为了解不同医疗机构在采用新技术方面遇到的障碍、工作流程整合方面的挑战以及对检验的期望提供了定性见解。

二次研究包括对同行评审文献、监管指南、临床试验註册库和公开文件进行系统性回顾，以揭示技术能力和监管发展轨迹。资料综合着重于跨多个资讯来源进行三角验证，以交叉检验论点并突显趋同趋势。分析方法包括对质性访谈进行主题编码、对部署模型进行比较评估以及基于情境的分析，以探讨供应链、政策和技术变革的影响。

整个研究过程中都强调了透明度和可重复性。研究结果与相关领域专家反覆审查，并根据回馈进行调整。建议充分考虑了新兴且异质性证据的局限性，并着重解决不同临床环境和监管管辖区之间的差异。

本文综合阐述了人工智慧在肿瘤诊断领域变革性的潜力，以及将创新转化为常规临床应用的关键步骤。

总之，人工智慧正在透过实现多模态分析、增强临床专业知识以及创造个人化治疗的新机会，推动癌症诊断的根本性变革。影像解读、基因组学和自然语言处理技术的进步正在推动治疗，它们各自提供互补的功能，以支持早期检测、更精准的肿瘤表征和更科学的治疗方案製定。成功的临床应用将取决于严格的检验、可互通的架构以及完善的管治，以确保准确性、公平性和永续性。

相关人员必须适应不断变化的经济和政策环境，同时优先考虑以病人为中心的治疗效果。对检验、基础设施和伙伴关係关係进行策略性投资，对于实现人工智慧诊断的愿景至关重要。注重透明度、跨部门合作和营运整合，将使医疗服务提供者和技术开发人员能够超越概念验证阶段，开发出可扩展的解决方案，从而显着改善诊断流程和临床决策。

归根究底，未来的发展之路需要兼顾技术性能、临床效用和实施可行性。致力于遵循这些原则的机构将更有能力发挥人工智慧的潜力，提高诊断准确性，并整体癌症治疗带来实际益处。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 透过整合多组体学数据和人工智慧，优化个人化癌症治疗方案
  • 开发可解释的人工智慧模型，以增强临床医生对自动化癌症诊断的信心
  • 联邦学习框架的出现，旨在保护跨机构人工智慧研究中的患者数据
  • 利用人工智慧主导的液态切片分析技术进行循环肿瘤DNA的非侵入性早期检测
  • 利用自然语言处理技术从非结构化病理报告中提取可操作的信息
  • 肿瘤手术中利用人工智慧进行即时病理影像分析的进展
  • 监管部门的核准加速了人工智慧癌症诊断平台在全球的商业化进程。
  • 在医疗服务不足地区实施边缘运算解决方案，用于照护现场AI辅助癌症筛检
  • 将人工智慧预测分析应用于电子健康记录中的模式，以对患者进行风险分层。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按应用程式分類的癌症诊断人工智慧市场

  • 影像诊断
    • CT影像
    • 磁振造影
    • PET影像
    • 超音波成像
  • 基因组分析
    • DNA定序
    • 表观遗传分析
    • RNA定序
  • 病理
    • 数位病理学
    • 组织病理学
  • 预测分析
    • 治疗结果预测
    • 风险评估
  • 治疗计划
    • 放射治疗计划
    • 手术计划

9. 癌症诊断领域人工智慧市场（按组件划分）

  • 硬体
  • 服务
    • 託管服务
    • 专业服务
  • 软体
    • 云端基础的
    • 本地部署

第十章 按最终用户分類的癌症诊断人工智慧市场

  • 诊断实验室
  • 医院和诊所
  • 製药公司
  • 研究所

第十一章：以癌症类型分類的人工智慧在癌症诊断市场的应用

  • 乳癌
  • 大肠直肠癌
  • 肺癌
  • 摄护腺癌

第十二章：按技术分類的癌症诊断人工智慧市场

  • 深度学习
  • 机器学习
  • 自然语言处理

第十三章 各地区癌症诊断人工智慧市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 癌症诊断领域人工智慧市场（按群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国癌症诊断人工智慧市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Siemens Healthineers AG
    • GE HealthCare Technologies Inc
    • Koninklijke Philips NV
    • Fujifilm Holdings Corporation
    • International Business Machines Corporation
    • Roche Diagnostics International AG
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Agilent Technologies, Inc.
    • Hologic, Inc.
Product Code: MRR-B16853776A7C

The AI in Cancer Diagnostics Market is projected to grow by USD 1,327.09 million at a CAGR of 22.23% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 266.28 million
Estimated Year [2025] USD 326.78 million
Forecast Year [2032] USD 1,327.09 million
CAGR (%) 22.23%

The rapid integration of artificial intelligence into cancer diagnostics is reshaping how clinicians detect, characterize, and manage oncologic disease. Advances in algorithmic interpretation, imaging enhancements, and molecular analytics are enabling earlier and more precise identification of malignancies, while simultaneously redefining workflows across pathology laboratories and radiology suites. These technological shifts are accompanied by growing stakeholder expectations for reproducibility, interpretability, and regulatory compliance as clinical teams seek tools that augment diagnostic confidence without disrupting established care pathways.

Emerging collaborations among technology developers, diagnostic laboratories, academic centers, and commercial partners are accelerating translation from pilot studies to routine clinical use. Meanwhile, improved data infrastructure and interoperability standards are facilitating multi-modal analyses that combine imaging, genomic, and clinical data to generate comprehensive patient profiles. As a result, institutions are evaluating not only the diagnostic performance of AI tools but also their operational fit, integration burden, and ability to deliver tangible improvements in patient throughput and outcomes.

Transitioning from proof-of-concept to scale requires nuanced decision-making that balances clinical value, technical readiness, and reimbursement pathways. Consequently, leaders in healthcare and diagnostics are prioritizing rigorous validation strategies, cross-disciplinary governance, and stakeholder education to ensure that AI-enabled solutions are adopted ethically, equitably, and sustainably within cancer care pathways.

How converging technologies, evolving workflows, and maturing regulatory and payer landscapes are accelerating systemic shifts in oncology diagnostics

The landscape of cancer diagnostics is witnessing transformative shifts driven by the convergence of computational power, data availability, and algorithmic sophistication. Deep learning models are achieving unprecedented capability in pattern recognition within radiology and pathology, while natural language processing is streamlining extraction of clinically relevant information from unstructured records. Concurrently, genomic profiling technologies are becoming more accessible and integrated with analytics platforms, enabling personalized diagnostic and therapeutic insights.

These technological advances are prompting redefinition of professional roles and workflows. Radiologists and pathologists are increasingly positioned as orchestrators of hybrid diagnostic processes, where automated pre-screening and triage are complemented by expert review for complex or ambiguous cases. In parallel, health systems are adopting cloud-first strategies to enable scalable deployments, yet they remain attentive to on-premises options where data sovereignty and latency concerns prevail. The result is a stratified adoption curve with pilot programs evolving into broader institutional implementations as stakeholders establish evidentiary frameworks and governance.

Importantly, the shift is not only technical but also economic and regulatory. Payers and policy bodies are reassessing coverage criteria as evidence accumulates, and regulatory pathways are maturing to accommodate algorithm updates and continuous learning systems. Together, these dynamics are accelerating a transition from isolated point solutions to integrated diagnostic ecosystems that prioritize clinical impact, interoperability, and long-term sustainability.

Assessing how the 2025 U.S. tariff adjustments reshaped supply chains, procurement strategies, and investment priorities across oncology diagnostics

The cumulative impact of U.S. tariffs introduced in 2025 has introduced new dynamics into sourcing, supply chain planning, and capital equipment procurement across the cancer diagnostics ecosystem. Devices and hardware components sourced from impacted jurisdictions have seen adjusted landed costs, prompting suppliers and health systems to reassess vendor contracts, inventory strategies, and maintenance agreements. These cost pressures have incentivized diversification of supply chains, greater emphasis on local manufacturing partnerships, and renewed scrutiny on total cost of ownership when evaluating diagnostic platforms.

Software and cloud-based services have also felt indirect consequences, as increased hardware procurement costs shift budgetary priorities and reframe investment timetables for IT modernization projects. In response, some organizations accelerated adoption of cloud-native analytics and software licensing models that decouple capital expenditures from operational capabilities. Others prioritized modular and interoperable software architectures to preserve flexibility in multi-vendor environments and to mitigate vendor lock-in risks exacerbated by shifting trade policies.

From a strategic perspective, stakeholders adapted by negotiating longer-term service agreements, seeking bundled offerings that include maintenance and training, and exploring co-development arrangements with technology vendors to localize production and support. As a result, emphasis on resilience, redundancy, and supply chain transparency has increased, shaping procurement decisions and partnership strategies among manufacturers, distributors, and healthcare providers.

Detailed segmentation analysis revealing how application, component, end-user, cancer-type, and technology distinctions shape adoption and product design in AI diagnostics

Segmentation insights reveal differentiated drivers of value across application areas, components, end users, cancer types, and enabling technologies. Diagnostic imaging continues to be a primary locus of AI deployment, where CT, MRI, PET, and ultrasound imaging workflows are being augmented with automated lesion detection, quantification, and longitudinal comparison tools that support earlier detection and standardized reporting. Genomic profiling, spanning DNA sequencing, epigenetic analysis, and RNA sequencing, is increasingly integrated with analytics platforms to support molecular subtyping and targeted therapy selection, while pathology workflows are evolving as digital pathology and histopathology tools enable remote review and AI-assisted morphologic analysis.

On the component axis, hardware investments in imaging systems and laboratory instrumentation are complemented by services models that encompass managed services and professional services to support implementation and ongoing optimization. Software choices remain pivotal, with cloud-based deployments offering scalability and centralized model management, while on-premises solutions retain appeal for institutions prioritizing data residency and regulatory control. End-user dynamics vary by setting: diagnostic laboratories focus on throughput and assay validation, hospitals and clinics prioritize point-of-care integration and workflow efficiency, pharmaceutical companies emphasize biomarker characterization for clinical trials, and research institutes prioritize experimental flexibility and data provenance.

Cancer type-specific considerations influence product design and adoption. Breast, colorectal, lung, and prostate cancer each present distinct imaging, molecular, and workflow requirements that inform algorithm training, validation cohorts, and clinical endpoints. Finally, technology segmentation across deep learning, machine learning, and natural language processing underscores complementary capabilities: deep learning excels at image-based interpretation, classical machine learning supports structured data prediction and risk stratification, and natural language processing unlocks insights from clinical narratives and pathology reports. Together, these segmented perspectives emphasize the need for interoperable solutions that can be tailored to clinical context and validated against robust, representative datasets.

How regional regulatory diversity, infrastructure capacity, and clinical practice patterns across Americas, EMEA, and Asia-Pacific drive differentiated AI diagnostics adoption strategies

Regional dynamics continue to shape strategic priorities, regulatory approaches, and adoption models across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, clinical adoption is often accelerated by integrated health systems and large academic centers that can support real-world validation studies; this environment fosters close collaboration between clinical leaders and technology vendors to operationalize pilot initiatives into enterprise deployments. Procurement decisions in this region emphasize interoperability with existing electronic health records and return-on-investment considerations tied to throughput and diagnostic accuracy improvements.

Across Europe Middle East & Africa, regulatory heterogeneity and varied reimbursement pathways influence deployment strategies. Institutions in this region frequently prioritize data governance, privacy compliance, and cross-border interoperability, while reimbursement frameworks can vary substantially between jurisdictions. As a result, vendors often pursue region-specific validation strategies and partnerships with local clinical networks to demonstrate clinical utility and to navigate regulatory submissions.

Asia-Pacific presents a diverse landscape driven by rapid digital adoption in some markets and constrained infrastructure in others. High-volume clinical settings in certain countries create compelling use cases for AI that improves efficiency and addresses workforce shortages in radiology and pathology. At the same time, investments in regional manufacturing and cloud infrastructure are shaping preferences for localized solutions. Overall, regional variation underscores the importance of flexible deployment models, culturally informed clinician engagement, and adaptive regulatory strategies to support sustainable adoption.

Analysis of vendor strategies and collaborative ecosystems showing how incumbents, pure-play AI developers, and cloud platforms accelerate clinical integration and commercialization

Key company dynamics reflect an ecosystem where traditional medical device and diagnostics firms, specialized AI vendors, cloud providers, and academic spin-outs each play distinct roles in shaping product innovation and commercialization. Established device manufacturers leverage their clinical relationships and distribution networks to integrate AI capabilities into imaging and laboratory platforms, while pure-play software companies focus on rapid iteration, algorithmic refinement, and interoperability across heterogeneous IT environments. Cloud providers and platform companies are enabling scalable model deployment and federated learning approaches that preserve data privacy while enhancing model generalizability.

Strategic partnerships and co-development agreements are prevalent as firms combine domain expertise with algorithmic proficiency to accelerate clinical validation and market access. Mergers and acquisitions remain an active pathway for technology consolidation, particularly where larger firms seek to incorporate specialized AI capabilities or expand into molecular diagnostics. Additionally, academic collaborations continue to underpin algorithm training and validation, offering access to curated datasets and clinical expertise that strengthen evidentiary packages.

For stakeholders evaluating vendor selection, considerations include clinical validation depth, regulatory track record, integration support, and long-term commitment to model maintenance and updates. Companies that demonstrate transparent performance metrics, robust validation across diverse cohorts, and clear pathways for post-market surveillance are more likely to secure institutional trust and long-term adoption.

Actionable strategic priorities for executives to validate, integrate, and commercialize AI diagnostics while ensuring operational readiness and ethical governance

Industry leaders should accelerate investments in rigorous clinical validation, governance frameworks, and interoperable architectures to ensure AI tools move from pilot phases to dependable clinical use. Prioritizing prospective clinical studies, multi-center validation, and transparent performance reporting will help secure clinician confidence and payer acceptance. In parallel, leaders should establish cross-functional governance committees that include clinicians, data scientists, ethicists, and IT professionals to manage model lifecycle, versioning, and bias mitigation efforts.

Operational readiness is equally important. Organizations should invest in scalable data pipelines, standardized annotation practices, and integration layers that enable AI outputs to be meaningfully incorporated into clinician workflows. Emphasis on modular software design and adherence to interoperability standards will reduce integration friction and preserve flexibility in multi-vendor environments. From a commercial perspective, consider flexible procurement and pricing models that align vendor incentives with clinical outcomes, such as value-based agreements and performance-linked contracts.

Finally, cultivate partnerships that localize implementation and support. Engaging with regional clinical networks, academic centers, and manufacturing partners can accelerate adoption while addressing supply chain resilience and regulatory navigation. By combining robust evidence generation with pragmatic operational planning and collaborative commercialization strategies, leaders can translate AI-enabled diagnostic advances into measurable improvements in patient care.

Robust mixed-methods research framework combining clinician interviews, literature synthesis, and iterative expert validation to ensure actionable and reproducible insights

The research methodology underpinning this analysis combined multi-modal evidence synthesis, stakeholder consultation, and iterative validation to ensure findings reflect practical realities and emergent trends. Primary inputs included structured interviews with clinical practitioners across radiology, pathology, and molecular diagnostics, complemented by consultations with technology leaders, procurement officers, and regulatory experts. These engagements provided qualitative insights into adoption barriers, workflow integration challenges, and validation expectations in diverse care settings.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance, clinical trial registries, and public filings to contextualize technological capabilities and regulatory trajectories. Data synthesis emphasized triangulation across multiple information sources to cross-validate claims and to surface convergent trends. Analytical techniques included thematic coding of qualitative interviews, comparative evaluation of deployment models, and scenario-based analysis to explore implications of supply chain, policy, and technological shifts.

Throughout the research process, emphasis was placed on transparency and reproducibility. Findings were iteratively reviewed with subject-matter experts and adjusted to account for feedback, ensuring that conclusions are grounded in both empirical evidence and practitioner experience. Limitations were acknowledged where evidence was emergent or heterogeneous, and recommendations were framed to accommodate variability across clinical contexts and regulatory jurisdictions.

Synthesis of the transformational potential of AI in oncology diagnostics and the critical steps required to translate innovation into routine clinical impact

In conclusion, AI is catalyzing a fundamental transformation in cancer diagnostics by enabling multi-modal analysis, augmenting clinical expertise, and creating new opportunities for personalized care. Progress is being driven by advances in imaging interpretation, genomic analytics, and natural language processing, each contributing complementary capabilities that support earlier detection, improved characterization, and more informed treatment planning. Successful translation into clinical practice hinges on rigorous validation, interoperable architectures, and thoughtful governance that together ensure accuracy, equity, and sustainability.

Stakeholders must adapt to evolving economic and policy contexts while prioritizing patient-centered outcomes. Strategic investments in validation, infrastructure, and partnerships will be critical to realize the promise of AI-enabled diagnostics. By focusing on transparency, cross-disciplinary collaboration, and operational integration, healthcare providers and technology developers can move beyond proof-of-concept initiatives toward scalable solutions that demonstrably improve diagnostic workflows and clinical decision-making.

Ultimately, the path forward requires balanced attention to technical performance, clinical utility, and implementation feasibility. Organizations that commit to these principles will be best positioned to harness AI's potential to enhance diagnostic precision and to deliver meaningful benefits across the cancer care continuum.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of multi-omics data with AI to refine personalized oncology treatment pathways
  • 5.2. Development of explainable AI models to increase clinician trust in automated cancer diagnostics
  • 5.3. Emergence of federated learning frameworks protecting patient data in cross-institutional AI research
  • 5.4. Adoption of AI-driven liquid biopsy analysis for non-invasive early detection of circulating tumor DNA
  • 5.5. Use of natural language processing to extract actionable insights from unstructured pathology reports
  • 5.6. Advancements in real-time AI-based histopathology image analysis during surgical oncology procedures
  • 5.7. Regulatory approvals accelerating commercialization of AI-enabled cancer diagnostic platforms globally
  • 5.8. Implementation of edge computing solutions for point-of-care AI-assisted cancer screening in underserved areas
  • 5.9. Incorporation of AI predictive analytics to stratify patient risk based on electronic health record patterns

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. AI in Cancer Diagnostics Market, by Application

  • 8.1. Diagnostic Imaging
    • 8.1.1. CT Imaging
    • 8.1.2. MRI Imaging
    • 8.1.3. PET Imaging
    • 8.1.4. Ultrasound Imaging
  • 8.2. Genomic Profiling
    • 8.2.1. DNA Sequencing
    • 8.2.2. Epigenetic Analysis
    • 8.2.3. RNA Sequencing
  • 8.3. Pathology
    • 8.3.1. Digital Pathology
    • 8.3.2. Histopathology
  • 8.4. Predictive Analytics
    • 8.4.1. Outcome Prediction
    • 8.4.2. Risk Assessment
  • 8.5. Treatment Planning
    • 8.5.1. Radiotherapy Planning
    • 8.5.2. Surgical Planning

9. AI in Cancer Diagnostics Market, by Component

  • 9.1. Hardware
  • 9.2. Services
    • 9.2.1. Managed Services
    • 9.2.2. Professional Services
  • 9.3. Software
    • 9.3.1. Cloud Based
    • 9.3.2. On Premises

10. AI in Cancer Diagnostics Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Hospitals And Clinics
  • 10.3. Pharmaceutical Companies
  • 10.4. Research Institutes

11. AI in Cancer Diagnostics Market, by Cancer Type

  • 11.1. Breast Cancer
  • 11.2. Colorectal Cancer
  • 11.3. Lung Cancer
  • 11.4. Prostate Cancer

12. AI in Cancer Diagnostics Market, by Technology

  • 12.1. Deep Learning
  • 12.2. Machine Learning
  • 12.3. Natural Language Processing

13. AI in Cancer Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. AI in Cancer Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. AI in Cancer Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Siemens Healthineers AG
    • 16.3.2. GE HealthCare Technologies Inc
    • 16.3.3. Koninklijke Philips N.V.
    • 16.3.4. Fujifilm Holdings Corporation
    • 16.3.5. International Business Machines Corporation
    • 16.3.6. Roche Diagnostics International AG
    • 16.3.7. Thermo Fisher Scientific Inc.
    • 16.3.8. QIAGEN N.V.
    • 16.3.9. Agilent Technologies, Inc.
    • 16.3.10. Hologic, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. AI IN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. AI IN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AI IN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CT IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CT IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CT IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CT IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CT IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CT IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MRI IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MRI IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MRI IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MRI IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MRI IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MRI IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PET IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PET IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PET IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PET IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PET IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PET IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY OUTCOME PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY OUTCOME PREDICTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY OUTCOME PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY OUTCOME PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY OUTCOME PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY OUTCOME PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RADIOTHERAPY PLANNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RADIOTHERAPY PLANNING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RADIOTHERAPY PLANNING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RADIOTHERAPY PLANNING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RADIOTHERAPY PLANNING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RADIOTHERAPY PLANNING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL PLANNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL PLANNING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL PLANNING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL PLANNING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL PLANNING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL PLANNING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROFESSIONAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROFESSIONAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROFESSIONAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROFESSIONAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROFESSIONAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROFESSIONAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CLOUD BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CLOUD BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CLOUD BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CLOUD BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CLOUD BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CLOUD BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ON PREMISES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ON PREMISES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ON PREMISES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ON PREMISES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ON PREMISES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ON PREMISES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MACHINE LEARNING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MACHINE LEARNING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MACHINE LEARNING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY MACHINE LEARNING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY GENOMIC PROFILING, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TREATMENT PLANNING, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA AI IN CANCER DIAGNOSTICS MARKET SIZE